Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228368 | 0.88 | LPAR1 (0.39) | MCHR1LPAR1LPAR5 | |
| SCHEMBL4240821 | 0.88 | TP53 (0.38) | MCHR1LPAR1LPAR5TP53POLB | |
| SCHEMBL4231972 | 0.87 | ALDH1A1 (0.40) | MCHR1LPAR1LPAR5TP53MET | |
| SCHEMBL4242456 | 0.83 | PKM (0.37) | MCHR1LPAR1LPAR5KMT2A | |
| SCHEMBL4229369 | 0.79 | CYP1A2 (0.40) | TP53METKMT2A | |
| SCHEMBL13699126 | 0.78 | CYP2D6 (0.48) | MCHR1LPAR1LPAR5HSD17B1HSD17B2 | |
| SCHEMBL4235504 | 0.77 | ALDH1A1 (0.41) | LPAR1LPAR5TTRPOLBKMT2A | |
| SCHEMBL4226767 | 0.76 | ALDH1A1 (0.36) | MCHR1LPAR1LPAR5METTTR | |
| SCHEMBL4241978 | 0.76 | PKM (0.36) | MCHR1LPAR1LPAR5KMT2A | |
| SCHEMBL4233732 | 0.75 | MCHR1 (0.35) | MCHR1LPAR1LPAR5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885LPAR1 277/4885LPAR5 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.